Bedrijfsoverzicht
Amicus Therapeutics, Inc. is a biotechnology entity dedicated to the discovery, development, and delivery of novel pharmaceutical treatments specifically targeting rare diseases across both the United States and international markets. The company operates within the Healthcare sector, functioning specifically in the Biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles rather than established consumer goods production. According to the latest available data, the company holds a market capitalization of $4.54 billion and reports trailing twelve-month revenue of $634.21 million, employing a workforce of 511 individuals. These financial figures indicate that Amicus Therapeutics maintains a significant market presence despite being in a specialized niche, suggesting a substantial operational scale relative to many other early-stage biotechnology firms.
Financiële gezondheid
The company generated $634.21 million in revenue over the trailing twelve months, yet reported a net income of -$27,110,000 and an EBITDA of $41.95 million. The substantial gap between positive revenue and negative net income reveals a cost structure where operating expenses significantly outpace gross profits, a common characteristic in biotechnology companies investing heavily in research, clinical trials, and regulatory compliance. Despite the net loss, the company reported positive free cash flow of $47.84 million, which provides essential financial flexibility to fund ongoing operations and R&D without relying immediately on external capital injections. Profitability metrics show a gross margin of 88.5%, indicating highly efficient production and pricing for its commercial products, while the operating margin stands at 8.6% and the profit margin is negative at -4.3%. The balance sheet shows a cash position of $293.54 million against total debt of $442.36 million, resulting in a debt-to-equity ratio of 161.30, which characterizes a leveraged balance sheet rather than a conservative one. However, the current ratio of 2.84 suggests robust short-term liquidity, indicating the company possesses sufficient current assets to cover its short-term liabilities with a comfortable buffer. Return on equity is negative at -11.6% and return on assets is 2.5%, revealing that management effectiveness is currently challenged by the lack of profitability, though asset utilization remains positive.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is not available due to the net loss, whereas the forward P/E is 17.66, implying that the market expects a significant turnaround in earnings trajectory or is valuing the company based on future anticipated profitability rather than current performance. The price-to-book ratio stands at 16.39, which indicates a substantial market premium over the company's book value, suggesting investors are pricing in significant future growth potential or asset appreciation. Alternative valuation metrics include a price-to-sales ratio of 7.16 and an EV/EBITDA of 111.78, both of which suggest the stock is priced at a high multiple relative to its sales and earnings generation capabilities, typical for biotechnology firms with pipeline value not yet reflected in cash flows. The 52-week trading range spans from a low of $5.51 to a high of $14.48, providing a clear context for current price volatility and historical trading bands. With a beta of 0.48, the stock exhibits lower price volatility relative to the broader market, indicating it moves less dramatically than the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is 23.7%, demonstrating strong top-line expansion, while earnings growth year-over-year is -95.5%, indicating that earnings are shrinking at a much faster rate than revenue, likely due to one-time costs or scaling expenses that have not yet been offset by profit improvements. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that it reinvests all available earnings back into growth initiatives such as clinical trials and product development rather than distributing cash to shareholders. This reinvestment strategy is standard for biotechnology companies that prioritize capital allocation toward expanding their therapeutic pipeline over providing immediate income to investors. The overall growth and income profile is defined by robust revenue expansion supported by positive cash flow, but tempered by a lack of current profitability and a leveraged capital structure that limits immediate shareholder returns.